A Phase 2/3 interventional study of danicamtiv and Placebo in Symptomatic Genetic Dilated Cardiomyopathy, sponsored by Kardigan, Inc.. Recruiting at 79 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Kardigan, Inc. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Cardiomyopathy, Dilated with a site in United States — 14 open to participants now, 20 under way, 2 of them phase 3. Cardiomyopathy, Dilated · United States.
Among the 64 studies in Cardiomyopathy, Dilated with a site in United States, this one is the 3rd largest by planned enrollment of the 42 interventional ones that give a count, is one of 5 that started in 2026, is the only one in phase 2/3, reaches primary completion later than 7 of the 19 other live ones, and was the 59th registered.
255 studies on the registry are indexed under Cardiomyopathy, Dilated; 66 are open to participants now.
Browse Cardiomyopathy, Dilated studies →14 of the 64 studies in Cardiomyopathy, Dilated with a site in United States are open now. Recruiting first, the newest first:
Affinia Therapeutics · Sites in United States, Canada
Ages 18–70
Kardigan, Inc. · Sites in United States, Belgium, Denmark and 8 more countries
Ages 18+
Nuevocor Pte. Ltd. · Sites in United States
Ages 18+
Rocket Pharmaceuticals Inc. · Sites in United States
Ages 18–65
Prolaio · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 53 Cardiomyopathy, Dilated studies recruiting now, 30 (57%) set no upper age limit and 15 (28%) stop at 75 or younger; 13 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 17 · Phase 3 5 · Phase 4 2
First in 1992; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 332 is above the median of 43 across 145 interventional studies indexed under Cardiomyopathy, Dilated.
Median enrollment 37 across the 42 interventional studies, 166 across the 20 observational. Of the 38 that completed or were terminated, 16 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 64 have an industry lead sponsor. The 10 most frequent:
Kardigan, Inc. is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Kardigan, Inc. has 2 studies filed under Cardiomyopathy, Dilated — fewer than ten, so there is no comparison to draw.
7 of the studies in Cardiomyopathy, Dilated with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07210723Phase 3Kardigan, Inc.A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy | 2027-09 |
| NCT04638621Ohio State UniversityDilated Cardiomyopathy-Cardiac Magnetic Resonance (DCM-CMR) Ancillary Study | 2026-12 |
| NCT06688396Lancaster General HospitalDilated Cardiomyopathy Detection Using AI and Screening With Mobile Technology (DCM-DETECT) | 2026-12 |
| NCT04476901Joshua M HareAdministration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy | 2027-04 |
| NCT06464588Emory UniversityA Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM) | 2027-07 |
Add all 7 to your calendar (.ics) → With an account.
Among the 64 studies in Cardiomyopathy, Dilated with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The Sponsor is studying an investigational medication called danicamtiv to determine if it can help people with genetic and familial dilated cardiomyopathy (DCM). Investigational means that the safety and effectiveness of danicamtiv have not been established. Currently, there are no approved drugs that are designed specifically to treat genetic or familial DCM.
The purpose of this study is to evaluate how well danicamtiv works compared to a placebo (sugar pill that looks like danicamtiv pill but does not contain any danicamtiv) and see how safe it is for people with genetic and familial DCM. In DCM, the heart muscle weakens and enlarges, making it harder for the heart to pump blood; this can happen for different reasons. Some people have DCM because of a change in a gene (called genetic DCM). Others may have DCM that runs in their family, even if no specific gene change is found (called familial DCM).
The main goals of the study are:
Participants will:
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: danicamtiv
Drug: Placebo
Danicamtiv will be administrated twice daily for up to 26 weeks
Placebo will be administrated twice daily for up to 26 weeks
Part 1: Change from Baseline (Day 1) to Week 26 in left atrial function index in Cohort 1
Time frame: 26 weeks
Part 2: Change from Baseline (Day 1) to Week 26 in peak VO2 in Cohort 1
Time frame: 26 weeks
Part 1: Change from Baseline (Day 1) to Week 26 in peak VO2
Time frame: 26 weeks
Part 1: Association between response in left ventricular global longitudinal strain and/or left atrial function index after 2 weeks of active treatment with placebo-adjusted Week 26 response in peak VO2
Time frame: 26 weeks
Part 1: Change from Baseline (Day 1) to Week 26 in left atrial function index in overall population
Time frame: 26 weeks
Part 1 and 2: Change from Baseline (Day 1) to Week 26 in left ventricular ejection fraction
Time frame: 26 weeks
Part 1 and 2: Change from Baseline (Day 1) to Week 26 in ventilatory efficiency
Time frame: 26 weeks
Part 1 and 2: Change from Baseline (Day 1) to Week 26 in Kansas City Cardiomyopathy Questionnare (KCCQ-23) Clinical Summary Score
All scores are represented on a 0-to-100-point scale, where lower scores represent more severe symptoms and/or limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life.
Time frame: 26 weeks
Part 1: Proportion of participants from Baseline (Day 1) to Week 26 who achieve at least a one-class improvement in New York Heart Association (NYHA) class
NYHA is a system used to categorize the severity of heart failure symptoms based on a patient's functional capacity, where 1 indicates no symptoms or limitations and 4 indicates symptoms present at rest.
Time frame: 26 weeks
Part 2: Change from Baseline (Day 1) to Week 26 in left atrial function index
Time frame: 26 weeks
Part 2: Change from Baseline (Day 1) to Week 26 in peak VO2 in the responder subgroup
Time frame: 26 weeks
Part 2: Change from Baseline (Day 1) to Week 26 in peak VO2 in overall population
Time frame: 26 weeks
Part 1 and 2: Change from Baseline (Day 1) to Week 26 in left ventricular global longitudinal strain
Time frame: 26 weeks
Part 1 and 2: Percent change from Baseline (Day 1) to Week 26 in NT-proBNP concentrations
Time frame: 26 weeks
Part 1 and 2: Characterization of peak (Cmax) of danicamtiv
Time frame: 20 weeks
Part 1 and 2: Characterization of trough (Cmin) plasma concentrations of danicamtiv
Time frame: 20 weeks
Part 1 and 2: Incidence and severity of treatment emergent adverse events, adverse events of special interest, serious adverse events and disease related events
Time frame: 26 weeks
Incidence of abnormal findings in laboratory assessments, physical examinations, 12-lead ECGs, and vital signs
Time frame: 26 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Sep 2027, 19 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Danicamtiv
Kardigan, Inc.